Lactobacillus paracasei NCU-04 and application thereof
The regulation of intestinal flora and neurotransmitters through Lactobacillus paracasei NCU-04 has solved the side effects and poor effects of existing constipation treatment methods, and achieved safe and efficient constipation relief and improvement of depression symptoms.
Patent Information
- Application Number
- CN202411331651.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-24
- Publication Date
- 2024-12-03
AI Technical Summary
The existing constipation treatment methods rely on drugs, have side effects such as diarrhea and abdominal pain, and the treatment of stubborn constipation is not effective, and there is a lack of safe and side-effect probiotic solutions.
Provide a strain of Lactobacillus paracasei NCU-04, which is screened from the feces of healthy breastfeeding infants and young children. It has the ability to grow, acid resistance, and antioxidant. It can regulate the balance of intestinal bacteria, inhibit specific pathogenic bacteria, and pass 5-HT signaling pathway improves constipation and depression symptoms.
Lactobacillus paracasei NCU-04 significantly relieves constipation symptoms, improves intestinal inflammation, regulates enteric neurotransmitters, increases fecal water content and intestinal peristalsis, relieves depression symptoms, and is free of hemolysis and antibiotic dependence.
Smart Images

Figure CN119060902A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of microorganisms, and in particular to a Lactobacillus paracasei NCU-04 strain and application thereof. Background Art
[0002] Constipation is a common, global condition characterized by decreased bowel movements, or difficult, strained, and dry stool. Constipation is believed to be primarily caused by diet, lifestyle, and social psychology. Three factors contribute to constipation: neuropsychological factors, intestinal motility factors, and abnormal intestinal bacteria. Constipation seriously impacts patients' physical and mental health. Approximately 10% of those with severe constipation develop colon cancer. Defecation in constipated patients can trigger cardiovascular and cerebrovascular disease attacks, potentially inducing angina pectoris, myocardial infarction, and other conditions.
[0003] The pathogenesis of constipation primarily involves decreased colonic contractility, pelvic floor and defecation dysfunction, abnormalities in enteric neurons and neurotransmitters, a decrease in cajal interstitial cells and enteric glial cells, and abnormal intestinal neurochemical signaling. Recent studies have demonstrated that intestinal dysbiosis is involved in the development and progression of chronic constipation. Disruption of the intestinal flora can affect the production of short-chain fatty acids, which in turn reduces glucagon production, inhibits intestinal transport function, and further impairs gastrointestinal motility. Numerous studies have demonstrated the potential benefits of probiotics in relieving and treating constipation. Probiotics can alter the composition of the intestinal flora in constipated patients, normalizing their microbial composition. They can also increase lactate and short-chain fatty acids in the intestinal environment, further lowering intestinal pH, promoting intestinal motility, and reducing transit time, thereby improving constipation symptoms. Probiotic metabolites also play a crucial role in regulating intestinal function, such as neural transmission and intestinal motility.
[0004] Currently, intractable constipation mainly relies on medication, but it has side effects such as diarrhea, abdominal pain, and drug dependence. Therefore, providing a probiotic that is effective in treating constipation and safe without side effects is a key research direction in this field. Summary of the Invention
[0005] The present invention aims to solve at least one of the technical problems in the prior art and provide a Lactobacillus paracasei NCU-04 and an application thereof.
[0006] The technical solutions of the present invention are as follows: The first aspect of the present invention provides a strain of Lactobacillus paracasei NCU-04, wherein the Lactobacillus paracasei ( Lactobacillus paracasei) NCU-04 was deposited in the General Microbiology Center of the China Culture Collection Administration on August 8, 2022, with the deposit number CGMCC No. 25506, and the deposit address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0007] Optionally, the 16S rDNA of the Lactobacillus paracasei NCU-04 has a nucleotide sequence as shown in SEQ ID NO.1.
[0008] Optionally, the Lactobacillus paracasei NCU-04 is screened from feces of healthy breastfed infants.
[0009] The second aspect of the present invention provides a microbial agent, which contains the Lactobacillus paracasei NCU-04 or its fermentation liquid or freeze-dried powder.
[0010] The third aspect of the present invention provides a product, which contains the Lactobacillus paracasei NCU-04 or the microbial agent according to claim 4.
[0011] The fourth aspect of the present invention provides the use of the Lactobacillus paracasei NCU-04 in the preparation of an antibacterial agent.
[0012] Optionally, the antibacterial agent can inhibit one or more of Salmonella typhimurium, Shigella flexneri, beta-hemolytic Streptococcus, Shigella dysenteriae, Escherichia coli O157, Staphylococcus enteritidis, Listeria monocytogenes and Staphylococcus aureus.
[0013] The fifth aspect of the present invention provides the use of the Lactobacillus paracasei NCU-04 in the preparation of a medicine for improving constipation.
[0014] The sixth aspect of the present invention provides the use of the Lactobacillus paracasei NCU-04 in the preparation of a medicine for treating colitis.
[0015] The seventh aspect of the present invention provides the use of the Lactobacillus paracasei NCU-04 in the preparation of a medicine for improving constipation accompanied by depressive-like behavioral symptoms.
[0016] The present invention has at least one of the following beneficial effects: The present invention provides Lactobacillus paracasei NCU-04 ( Lactobacillus paracaseiNCU-04, isolated from the feces of healthy breastfed infants, exhibits strong growth and reproduction capabilities, acid resistance, and antioxidant capacity, is non-hemolytic, and is sensitive to specific antibiotics. Its bacterial suspension and fermentation broth exhibit potent inhibitory effects against Salmonella typhimurium, Shigella flexneri, β-hemolytic Streptococcus, Shigella dysenteriae, Escherichia coli O157, Staphylococcus enteritidis, Listeria monocytogenes, and Staphylococcus aureus. In a constipation mouse model, this strain effectively alleviated constipation symptoms by regulating intestinal microbiota balance, alleviating intestinal inflammation, and modulating enteric neurotransmitters. It also improved depressive symptoms in constipated mice through the 5-HT signaling pathway. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 The results of the in vitro probiotic performance evaluation of Lactobacillus paracasei NCU-04 are shown in Figure 1, where A is the growth curve, B is the hemolytic activity result, C is the acid resistance result, D is the antioxidant activity, E is the antibiotic susceptibility test, and F is the antibacterial test. Figure 2 Figure 1 shows the test results of Lactobacillus paracasei NCU-04 in alleviating constipation and colon inflammation in mice. A: Flowchart of the animal model evaluation experiment, B: Fecal water content, C: Time to first black stool, D: Gastrointestinal transit rate, E: HE staining, FH: Transcription levels of TNF-α, IL-6, and IL-1β, respectively. Figure 3 The results of the test of Lactobacillus paracasei NCU-04 improving constipation by regulating the expression of aquaporins and gastrointestinal hormones are shown in Figure 1. A: Western blot results of VIP and AQP3 proteins, B: relative expression of VIP, C: relative expression of AQP3, D: MTL level, E: PYY level, F: 5-HT level, G: c-kit protein-positive cells. Figure 4 This is a test result diagram showing that Lactobacillus paracasei NCU-04 regulates the expression of brain 5-HT and its receptors to relieve constipation, where A: mouse brain 5-HT, BC: 5-HT4R expression; Figure 5Figure 2 shows the test results of Lactobacillus paracasei NCU-04 regulating intestinal flora imbalance caused by constipation, including: AC: α-diversity assessment results of intestinal flora, D: PCoA principal component analysis, E: family-level changes in intestinal microbial composition, F: abundance of s24-7, G: abundance of Rikenellaceae, H: genus-level changes in intestinal microbial composition, I: relative abundance of Odoribacter, J: relative abundance of Prevotella, K: correlation between 5-HT, MTL, PYY and VIP and Provetella, Lactobacillus, Rikenella and Odoribacter; Figure 6 This is a test result diagram showing that Lactobacillus paracasei NCU-04 can improve the depressive symptoms of constipated mice through 5-HT signaling, including: A: Animal experimental process of tryptophan hydroxylase inhibitor inhibiting the synthesis of 5-HT in constipated mice, B: Sucrose water preference experiment, C: Tail suspension experiment, D: 5-HT content in mouse colorectal tissue, E: 5-HT content in mouse brain tissue, F: Expression level of 5-HT4R, G: Expression level of BDNF. DETAILED DESCRIPTION
[0018] In order to make the technical problems, technical solutions and beneficial effects solved by the present invention more clearly understood, the present invention is further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.
[0019] Example 1 Screening of strains and in vitro property experiments 1. Screening, isolation and identification of strains: a) Dilution and coating: After obtaining a fresh fecal sample from a newborn, perform a gradient dilution of 10 0 -10 7 , take 10 1 , 10 3 , 10 4 , 10 5 Gradient plating was performed, with 30 μl applied to each MRS plate, and cultured under anaerobic and aerobic conditions for 48 h, respectively.
[0020] b) Inoculation of culture medium: Take a plate with 200-400 colonies and, in a sterile clean bench, select colonies that are of good morphology, size, color, size, neat edges, and rapid growth. Pick 5-10 single colonies and inoculate them into 5 ml of the corresponding MRS liquid culture medium for aerobic and anaerobic activation and culture for 48 h.
[0021] c) Identification and Preservation: The activated bacterial solution was preserved, and the remaining bacterial solution was centrifuged and subjected to crude DNA extraction, followed by high-throughput sequencing. The bacterial solution identified as Lactobacillus paracasei by sequencing was reactivated and then re-identified using bidirectional sequencing. The Lactobacillus paracasei strains with accurate identification results were preserved for subsequent experiments.
[0022] The screened and isolated strain was named Lactobacillus paracasei NCU-04. After identification, the 16S rDNA sequencing result of Lactobacillus paracasei NCU-04 was shown in SEQ ID NO: 1:
[0023] Lactobacillus paracasei ( Lactobacillus paracasei ) NCU-04 was deposited in the General Microbiology Center of the China Culture Collection Administration on August 8, 2022, with the deposit number CGMCC No. 25506, and the deposit address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0024] Example 2 In vitro property experiments 1. Growth curve of strain: The growth curve was determined using turbidimetry. Since the concentration of a bacterial suspension is proportional to its turbidity, the optical density of the bacterial suspension can be measured spectrophotometrically to infer the concentration of the bacterial suspension. Lactobacillus paracasei strains were activated overnight, and 1 mL was inoculated into 100 mL of MRS liquid medium. The culture was anaerobically incubated at 37°C. The optical density was measured at a wavelength of 600 nm at 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours. A growth curve was plotted with time on the horizontal axis and optical density on the vertical axis.
[0025] 2. Acid resistance test of Lactobacillus paracasei (1) Place Lactobacillus paracasei in the corresponding liquid culture medium in an anaerobic incubator and culture at 37°C for 48 hours, and retain the strain for future use; (2) Dilute the culture medium to 10 with MRS 10 CFU / mL, take 1 mL of each and centrifuge at 4,000 rpm for 3 min and discard the supernatant; add 1 mL of PBS buffer with pH 3, 4, 5, and 7, respectively, keep at 37°C for 4 h, dilute serially with PBS, mix well, take 100 μl and spread on the plate, incubate in a 37°C anaerobic incubator for 48 h, and count the viable bacteria to observe the viable bacteria of the strain in different acid environments; 3. Experimental evaluation of the antioxidant activity of Lactobacillus paracasei (1) Determination of DPPH free radical scavenging ability: 2 mL of bacterial lysate supernatant was added with 2 mL (0.2 mmol / L) DPPH methanol solution (experimental group), and the reaction was carried out at room temperature in the dark for 30 min. The supernatant was collected and the OD was measured at 517 nm. The control group was 2 mL of deionized water plus DPPH methanol solution: DPPH free radical scavenging rate = [1-A517 (sample) / A517 (blank)] × 100% Among them, A517 (sample) is the OD value of the experimental group at 517 nm, and A517 (blank) is the OD value of the control group at 517 nm.
[0026] (2) Determination of hydroxyl radical scavenging ability: Take 1 mL of 2 mmol / L FeSO4 solution, 1 mL of 6 mmol / L H2O2, and 1 mL of 6 mmol / L salicylic acid, add 1 mL of bacterial lysate supernatant (experimental group), let it stand at room temperature for 30 min, use deionized water as the blank control group, measure the absorbance at 510 nm, and calculate the scavenging rate of hydroxyl free radicals: Hydroxyl radical scavenging rate = [1-A510 (sample) / A510 (blank)] × 100% Among them, A510 (sample) is the OD value of the experimental group at 510 nm, and A510 (blank) is the OD value of the blank control group at 510 nm.
[0027] (3) Determination of superoxide radical scavenging ability Group A11: 2 mL of 150 mmol / L Tris-HCl solution (pH 8.0) and 1 mL of 1.2 mmol / L pyrogallol solution were added to 0.5 mL of bacterial lysate supernatant, respectively. The mixture was reacted at room temperature for 30 min, and the absorbance at 330 nm was measured. Group A10: The only difference from A11 is that it does not contain pyrogallol; Group A01: The only difference from Group A11 is that it does not contain bacterial culture medium; Group A00: The only difference from Group A11 is that it does not contain bacterial culture medium and pyrogallol; Superoxide radical scavenging rate = [1-(A11-A10) / (A01-A00) × 100% Among them, A00 is the absorbance of group A00 at 330 nm; A01 is the absorbance of group A01 at 330 nm; A10 is the absorbance of group A10 at 330 nm; A11 is the absorbance of group A11 at 330 nm.
[0028] (4) Fe 2+ Determination of chelating capacity: Experimental group: 0.1 mL of 0.4% ferrous sulfate solution was added to 0.5 mL of sample solution. After gently inverting to mix, 0.1 mL of 1% VC and 1 mL of 0.2 mol / L NaOH solution were added. The mixture was reacted at room temperature for 20 min. Then, 1 mL of 10% trichloroacetic acid was added and the mixture was centrifuged at 6,000 rpm at 4°C for 10 min to remove protein. 0.4 mL of the above solution was taken and 4 mL of 0.1% phenanthroline was added. The mixture was reacted at room temperature for 10 min. The absorbance at 536 nm was measured. Blank group: Sterile saline or PBS as blank control Fe 2+Chelating capacity = [A blank - A sample / A blank] × 100% Among them, A blank is the absorbance of the blank group, and A sample is the absorbance of the experimental group.
[0029] (5) Determination of total reducing power To 1 mL of bacterial lysate, add 1 mL of phosphate buffer (pH 6.6) and 1 mL of 1% K₃[Fe(CN)₆] solution. Mix thoroughly by inverting the tube. Incubate at 50°C for 2 minutes. Add 1 mL of 10% trichloroacetic acid solution and vortex to mix thoroughly. Add 4 mL of deionized water and 0.4 mL of 0.1% FeCl₃ solution to 1 mL of the mixture and let it stand for 10 minutes. Measure the absorbance at 700 nm using deionized water as a blank. A higher absorbance value indicates a stronger reducing power of the analyte.
[0030] 4. Antibacterial test of Lactobacillus paracasei (1) Lactobacillus paracasei was inoculated into the corresponding liquid culture medium, cultured in an anaerobic incubator at 37°C for 48 h, and centrifuged at 6,000 g for 5 min; (2) 10 8 Spread CFU of Salmonella typhimurium, Shigella flexneri, Propionibacterium dysenteriae, Shigella dysenteriae, enterohemorrhagic Escherichia coli, Streptococcus enteritidis, Listeria monocytogenes, Staphylococcus aureus, and Candida albicans onto LB solid medium. Gently place an Oxford cup on the plate and pipette 250 μl of the probiotic culture supernatant and lysate supernatant into the Oxford cup (per group, perform two replicates). Incubate at 37°C. Observe the size of the inhibition zone every 2 hours. Measure the diameter of the inhibition zone after 8 hours and keep records.
[0031] 5. Hemolysis test of Lactobacillus paracasei (1) Prepare a solid nutrient agar medium containing an appropriate proportion of sterile defibrinated goat blood; (2) Prepare the culture medium of Lactobacillus paracasei to be tested in advance, ensure that it is in the active growth phase, and use Staphylococcus aureus as a positive control. Add 20 μl of Lactobacillus paracasei suspension and 20 μl of Staphylococcus aureus suspension respectively on the plate and culture at 37°C; (3) After the culture is completed, carefully observe whether there is a clear ring around the colonies on the plate. The appearance of a ring indicates that hemolysis has occurred.
[0032] 6. Antibiotic susceptibility test of Lactobacillus paracasei (1) A paper sheet soaked with various antibiotics is placed on an agar plate coated with Lactobacillus paracasei. The drugs contained in the paper sheet absorb the water in the agar and dissolve, then continue to diffuse from the center of the paper sheet to the surrounding area, forming a decreasing gradient concentration. (2) The growth of the bacteria to be tested is inhibited within the antibacterial concentration range around the paper, thereby producing a transparent inhibition zone, and the diameter of the transparent zone is observed; (3) The size of the inhibition zone diameter reflects the sensitivity of the tested bacteria to antimicrobial drugs, that is, the larger the inhibition zone, the smaller the minimum inhibitory concentration value.
[0033] Test results and analysis: The above test results are as follows Figure 1 shown.
[0034] The growth curve showed that NCU-04 had strong growth performance. After 20 hours of culture, the bacterial density (OD 600 ) can reach 2.5 or more ( Figure 1 A), indicating that it has great advantages in industrial production.
[0035] In contrast to the pathogen Staphylococcus aureus, Lactobacillus paracasei NCU-04 showed no hemolytic activity ( Figure 1 B).
[0036] The acid resistance results showed that the strain could survive at pH 2.0-3.0 in the absence of any additional protective agents ( Figure 1C ).
[0037] We used total bacterial lysate (bacterial fluid) to test the antioxidant activity of Lactobacillus paracasei NCU-04. The results showed that NCU-04 had scavenging rates of approximately 67.62% for superoxide anions, 86.86% for hydroxyl radicals, and 87.57% for DPPH radicals (Figure 1D). Furthermore, its chelating capacity for ferrous ions was 68.50%, and its total reducing capacity (A700) value was 0.71 (Figure 1D).
[0038] Antibiotic susceptibility testing showed that Lactobacillus paracasei NCU-04 was resistant to minocycline (MY), cephalosporin (CTR), ciprofloxacin (CIP), gentamicin (GEN), and succinate-trimethoprim-sulfamethoxazole (SXT), but was not resistant to chloramphenicol (C), penicillin (PEN), ampicillin (AMP), tetracycline (TET), and erythromycin (E) ( Figure 1E ).
[0039] In addition, by Figure 1 It can be seen that the fermentation supernatant and bacterial lysate of Lactobacillus paracasei NCU-04 were effective against common pathogens including Salmonella typhimurium ATCC 13311 ( Figure 1 No. 1 in F), flexneri ATCC 12022 ( Figure 1 Number 2 in F), β-hemolytic Streptococcus ( Figure 1 Number 3 in F), Shigella dysenteriae 301 ( Figure 1Number 4 in F), Escherichia coli O157 ( Figure 1 No. 5 in F), Staphylococcus enteritidis ATCC 13076 ( Figure 1 No. 6 in F), Listeria monocytogenes ATCC 19111 ( Figure 1 No. 7 in F), Staphylococcus aureus Cowan1 ( Figure 1 No. 8 in F) had an inhibitory effect, and the antibacterial activity of the bacterial lysate was stronger than that of the fermentation broth.
[0040] The above results indicate that Lactobacillus paracasei NCU-04 has good prebiotic properties and safety, can play an effective prebiotic role in the intestine, and has development prospects.
[0041] Example 3: Lactobacillus paracasei promotes 5-HT synthesis, intestinal motility, and constipation In order to explore the effect of Lactobacillus paracasei NCU-04 on constipation, the present invention designed an animal model evaluation experiment according to the experimental flow chart ( Figure 2 A).
[0042] Animal experiments: 1. Mouse Phenotype Monitoring (1) Determination of water content in mouse feces: After the treatment, place each mouse in a cage lined with absorbent paper, collect feces, and weigh them as wet weight. After drying, the dry weight is obtained. The water content of feces is calculated according to the formula: Fecal moisture content / % = (fecal wet weight - fecal dry weight) / fecal wet weight × 100% (2) Time when mice first excrete black stool: On the last day of treatment, 1 hour after gavage, each mouse was gavaged with 200 μl of ink, and the time when the mice in each group passed the first black stool was recorded.
[0043] (3) Mouse intestinal propulsion rate detection: After treatment, mice were fasted overnight with or without water to empty their intestinal contents. Intestinal propulsion rate was measured the following morning. The specific method: Each mouse was orally administered 200 μl of ink. 30 minutes later, the mouse was sacrificed. The abdominal cavity was opened, and the entire intestine from the pylorus to the anus was removed. After being stretched without tension, the total intestinal length (L1) was measured, and the length of ink traveled within the intestine (L2) was measured.
[0044] Small intestinal propulsion rate D = L2 / L1 × 100% 2. Colorectal Pathological Manifestations 1. HE staining (goblet cells, mucin): Tissue sections allow for better visualization of the intestinal microstructure of different groups of mice. Paraffin-embedded and sectioned distal colon tissue from mice revealed intact epithelial cells in the blank group, without signs of atrophy, erosion, or necrosis. Cells were neatly arranged, interspersed with goblet cells, and the villi were abundant, consistent with the microstructural changes observed in the distal colon of healthy mice. However, after loperamide hydrochloride-induced constipation in mice, colonic tissue was affected accordingly. Epithelial cells shed, the muscle layer thinned, and concave defects formed on the mucosal surface. The small intestinal mucosal cells showed uneven arrangement, and the number of goblet cells decreased. Further studies revealed that oral administration of Lactobacillus paracasei restored some of the morphological characteristics of the intestinal mucosa in the constipated mice. The cell arrangement of the colonic tissue became increasingly uniform, and the depth of the folds deepened. The colonic features of the high-dose group resembled those of the blank group.
[0045] 2. ELISA detection of neurotransmitter 5-HT and SP content in colon and brain tissue 5-HT, a type of brain-gut peptide, is an important neurotransmitter in the brain-gut axis. It has the function of regulating neural activity and is also an important gastrointestinal signaling molecule. 5-HT is distributed in both the gastrointestinal tract and the central nervous system. Changes in its content in the gastrointestinal tract can alter gastrointestinal activity and internal environment homeostasis. Changes in 5-HT in the central nervous system can also cause gastrointestinal reactions. Studies have shown that 5-HT can not only act directly on smooth muscle to promote intestinal motility, but also exert its effects by binding to different receptors. Binding to 5-HT3AR affects the release of excitatory neurotransmitters and affects extracellular Ca. 2+ The concentration of 5-HT4R regulates the activity of ICCs and promotes gastrointestinal motility. After binding with 5-HT4R, it can increase the slow wave amplitude of ICCs and coordinate axon signal transmission. In addition, 5-HT4R itself, as a protein-coupled receptor, can also promote the release of neurotransmitters such as Ach, thereby affecting the contraction of gastrointestinal smooth muscle and affecting intestinal motility function.
[0046] Colon and brain tissue were used for 5-HT testing. Gently rinse the colon and brain tissue with pre-chilled saline to remove any residual impurities and surrounding fat. An appropriate amount of tissue was excised and accurately weighed. Add pre-chilled saline to the tissue at a ratio of 1:9 (tissue: saline) (g:mL). Thoroughly grind the tissue, centrifuge, and aliquot the supernatant. 5-HT was assayed according to the ELISA kit instructions.
[0047] 3. Immunohistochemical detection of c-kit protein to assess the amount of ICC and detection of 5-HTR4; ICC: (1) Dehydration and paraffin embedding: The colorectal tissues of mice in each group were selected, fixed in 4% paraformaldehyde, and dewaxed; (2) Sectioning: Cutting fixed samples into very thin tissue sections, usually 4-6 µm; (3) Antigen retrieval: Place the slide in a dish containing antigen retrieval solution and boil it (10 min). After cooling to room temperature, wash it twice with PBS buffer. (4) Blocking of endogenous catalase: Incubate in 3% H2O2 aqueous solution for 8 min in the dark, and rinse twice with PBS buffer; (5) Serum blocking: add 5% calf serum and incubate at room temperature for 30 min; (6) Antibody labeling: Prepare the primary antibody and select the corresponding secondary antibody according to the antibody instructions. Incubate the primary antibody at 4°C overnight (protected from light) and incubate the secondary antibody at room temperature for 40 min. (7) Antibody staining: Add DAB working solution and incubate in the dark for 8 min. After rinsing with ddH2O to terminate the reaction, add hematoxylin for 30 s and rinse with ddH2O for 8 min. (8) Microscopic analysis: Observe the expression of c-kit under a microscope.
[0048] 5-HTR4: (1) Dehydration and paraffin embedding: The colorectal tissue and brain tissue of each group of mice were selected, fixed in 4% paraformaldehyde, and dewaxed; (2) Sectioning: Cutting fixed samples into very thin tissue sections, usually 4-6 µm; (3) Antigen retrieval: Place the slide in a dish containing antigen retrieval solution and boil it (10 min). After cooling to room temperature, wash it twice with PBS buffer. (4) Blocking of endogenous catalase: Incubate in 3% H2O2 aqueous solution in the dark for 8 min, then rinse twice with PBS buffer; (5) Serum blocking: add 5% calf serum and incubate at room temperature for 30 min; (6) Antibody labeling: Prepare the primary antibody and select the corresponding secondary antibody according to the antibody instructions. Incubate the primary antibody overnight at 4°C (protected from light) and incubate the secondary antibody at room temperature for 40 min. (7) Antibody staining: Add DAB working solution and incubate in the dark for 8 min. After rinsing with ddH2O to terminate the reaction, add hematoxylin for 30 s and rinse with ddH2O for 8 min. (8) Microscopic analysis: Observe and record the expression of 5-HT4R under a microscope.
[0049] 3. Blood Gastrointestinal Hormone Regulatory Peptide Detection (1) Detection of the levels of gastrointestinal peptide (MTL) and peptide tyrosine yrosine (PYY) in mouse serum: The collected mouse blood was allowed to stand for 2 h and centrifuged at 3000×g for 15 min to obtain serum. The experiment was performed according to the instructions of the corresponding kit, and the concentrations of motilin (MTL) and peptide tyrosine yrosine (PYY) in the serum were calculated based on the standard curve.
[0050] 4. Detection of colorectal-specific proteins and inflammatory factors (1) Detection of VIP and AQP3 protein expression using Western-Blot: Colon tissues from mice in each group were selected, homogenized, lysed using RIPA lysis buffer (Solarbio, China, R0010), and centrifuged to obtain protein (1000 rpm, 20 min); (1) Glue preparation: After leak detection, prepare separation gel of appropriate concentration according to the molecular weight of the target protein. After adding the concentrated gel, insert the gel comb and wait for solidification; (2) Sample loading: After the protein sample is thoroughly mixed, add it to the gel well, place it in the electrophoresis tank and add the electrophoresis solution. Set the constant voltage to 80 V for 20 min, and then set the voltage to 180 V for 1 h. (3) Transfer: After electrophoresis, retain the target protein band area, place PVDF pre-excited with methanol on the target fragment, set a constant current of 260 mA, and transfer for 80 min; (4) Blocking: Prepare 5% skim milk and incubate at room temperature for 1 h; (5) Antibody incubation: Incubate the primary antibody with the target band in a refrigerator at 4°C overnight, wash the membrane three times with 1×TBST, select the corresponding secondary antibody according to the primary antibody, incubate at room temperature for 1 h, and wash the membrane three times; (6) Development: Prepare exposure solution and perform exposure.
[0051] (2) Detection of TNF-α, IL-1β, and IL-6 expression in colon tissue using q-PCR: q-PCR was used to detect intestinal proinflammatory factors to evaluate the inhibitory effect of Lactobacillus paracasei on intestinal inflammation. Intestinal dysbiosis can lead to the overgrowth of Gram-negative enteric pathogens, a significant reduction in probiotics, and the production of large amounts of endotoxins (LPS), which increase intestinal permeability. After substantial absorption of endotoxins, they activate the transcription factor NF-κB via TLR4, promoting the release of inflammatory factors such as TNF-α, IL-1β, and IL-6, further exacerbating intestinal mucosal damage, intestinal bacterial translocation, and endotoxin absorption, creating a vicious cycle. Phenyllactic acid, a metabolite of Lactobacillus paracasei, has a broad antibacterial spectrum, inhibiting Gram-negative and Gram-positive bacteria, as well as fungi, thereby inhibiting the growth of intestinal pathogens and exerting an anti-inflammatory effect.
[0052] 5. Intestinal flora recovery and metabolite determination (1) 16SRNA detection of mouse fecal flora recovery: Fecal Collection: Feces were collected from each group of mice before the start of the experiment and after treatment. Each mouse was placed individually in a sterile beaker. After defecation, feces were quickly collected with sterile forceps and placed into a 2 ml sterile cryotube. Quickly frozen in liquid nitrogen, the feces were stored at -80°C. Three to five feces were collected from each mouse, ensuring they were not wetted by urine. High-throughput sequencing was used to analyze the richness, distribution, and diversity of the gut microbiota in each group.
[0053] Test results and analysis: The above test results are as follows Figures 2 to 5 shown.
[0054] like Figure 2 As shown in Figures BD, compared with the normal control group (Group C), the defecation parameters of mice in the model group (Group M) were significantly altered, including decreased fecal water content (56.74 ± 4.56% vs. 27.90 ± 3.32%, p < 0.01), longer defecation time to first black stool (160.80 ± 25.90 min vs. 320.40 ± 34.27 min, p < 0.01), and slower gastrointestinal transit rate (54.33 ± 3.11% vs. 13.11 ± 2.92%, p < 0.01), indicating that loperamide hydrochloride modeling effectively induced constipation in mice. However, compared with Group M, the defecation parameters of mice in the treatment groups, including the positive drug control group (Group Y), the low-dose NCU-04 group (Group L), and the high-dose NCU-04 group (Group H), were significantly improved. Notably, fecal water content and time to first black stool in group L were comparable to those in group Y (p>0.05), but their gastrointestinal transit rate was weaker (p<0.01). Interestingly, the therapeutic effect was more pronounced in group H compared with group L, indicating that the therapeutic effect of NCU-04 on constipation is dose-dependent.
[0055] The results of colon eosin-methylene blue staining (HE staining) showed that compared with group C, the colon muscle layer of mice in group M was significantly thinner, accompanied by obvious inflammatory cell infiltration, a significant decrease in the number of goblet cells, and destruction of colonic crypts ( Figure 2 E). In contrast, the colon pathology of mice in groups Y, L, and H improved to varying degrees, indicating that NCU-04 treatment effectively alleviated the pathological changes in the colon of constipated mice (Figure 2E).
[0056] In addition, compared with group C, the transcription levels of inflammatory factors (including TNF-α, IL-6, and IL-1β) in the colon of mice in group M were significantly upregulated (p<0.01); compared with group M, the transcription levels of these inflammatory factors in groups Y, L, and H were significantly decreased, and the effect of group H was the most ideal (Figure 2F-H).
[0057] These results indicate that Lactobacillus paracasei NCU-04 alleviated dyspnea and colonic inflammation in loperamide-induced constipated mice.
[0058] It is well known that the occurrence of constipation is closely related to gastrointestinal motility. Vasoactive intestinal peptide (VIP), as an inhibitory neurotransmitter distributed in the submucosal, intermuscular and nervous systems of the gastrointestinal tract, has the effect of relaxing smooth muscle and inhibiting gastrointestinal motility. In addition, VIP can regulate intestinal water metabolism by regulating the expression of aquaporin 3 (Aquaporin 3, AQP3) in intestinal epithelial cells. When the expression level of AQP3 increases, the intestinal contents will lose too much water, leading to difficulty in defecation and constipation. Therefore, in order to further explore the molecular mechanism of NCU-04 in improving constipation, we used Western blotting to detect the expression of VIP and AQP3 proteins ( Figure 3 A). The results showed that compared with the M group, the expression levels of VIP and AQP3 were reduced after intervention with NCU-04 and positive drugs, and the effect of the H group was more significant ( p <0.01) ( Figure 3 BC).
[0059] VIP is distributed throughout the gastrointestinal tract. Vasoactive intestinal peptide (VIP) is an inhibitory neurotransmitter widely distributed in the submucosal and myenteric regions of the gastrointestinal tract and the nervous system. It relaxes smooth muscle, inhibits gastrointestinal motility, and slows intestinal emptying. It is a key neurotransmitter in the "brain-gut axis." VIP acts directly on VIP receptors on gastrointestinal smooth muscle. Its primary physiological functions are promoting glycogenolysis, stimulating gastrointestinal mucosal secretions, and lowering lipids. Most studies have shown that VIP levels are elevated in patients with chronic constipation.
[0060] AQPs are closely linked to constipation, regulating water absorption and secretion in the colon. AQP3, one of 13 water channel proteins in the AQP family, is primarily found in the colon and is crucial for transporting and secreting digestive fluids. When AQP3 expression levels increase in the colon, the osmotic pressure within the colonic lumen is lower than that within the blood vessels. As a result, water is transported from the lumen to the vascular side via AQP3, causing intestinal contents to lose excess water. Feces in the colon become hardened and aggregated, leading to difficulty in defecation and constipation.
[0061] To further investigate the effects of NCU-04 on constipation-related gastrointestinal regulatory neurotransmitters, we evaluated the levels of the excitatory neurotransmitter motilin (MTL) and the inhibitory neurotransmitter peptide YY (PYY) in the colon tissue of constipated mice. The results showed that the MTL level in the blood of mice treated with NCU-04 was significantly lower than that in the control group ( p <0.01, while the level of PYY was significantly increased ( p <0.01); compared with the M group, the expression level of MTL in the H group was increased ( p <0.01), while the expression level of PYY was significantly decreased ( p <0.01) ( Figure 3 D and E). This suggests that Lactobacillus paracasei can improve constipation by regulating the expression of gastrointestinal neurotransmitters and aquaporins.
[0062] MTL is a gastrointestinal peptide hormone that regulates human gastrointestinal motility and stimulates intestinal peristalsis. MTL promotes segmental motility in the small intestine, thereby shortening the transit time of chyme in the small intestine. Oral administration of loperamide also reduces MTL concentrations in mouse serum, while Lactobacillus paracasei can restore serum MTL levels to normal, suggesting that it alleviates constipation by improving gastrointestinal peptide levels.
[0063] PYY is a gastrointestinal hormone, a 36-amino acid peptide secreted by enteroendocrine L cells. Intraperitoneal injection of PYY in mice revealed an inhibitory effect on colonic propulsion, with levels upregulated in the model group. However, after probiotic treatment, serum PYY levels in mice were significantly downregulated compared to the model group.
[0064] Serotonin, also known as 5-hydroxytryptamine (5-HT), is a neurotransmitter of brain-gut peptides that regulates neural activity. It is also an important gastrointestinal signaling molecule, and changes in its content can also cause gastrointestinal reactions. The results showed that compared with the C group, the 5-HT content in the colon tissue of mice in the M group was significantly reduced; and compared with the M group, all treatment groups were able to significantly increase the 5-HT content in the colon of constipated mice; among them, the effect of the H group was the most obvious ( Figure 3 F). These results indicate that Lactobacillus paracasei NCU-04 can significantly increase the level of 5-HT in the intestine of constipated mice, thereby improving constipation.
[0065] Furthermore, interstitial cajal cells (ICCs) exist in the human digestive system. Numerous studies have demonstrated that a decrease in ICC numbers and morphological changes contribute to gastrointestinal dysfunction. The tyrosine kinase receptor protein c-kit is closely associated with ICC function. Knocking out c-kit results in ICC dysfunction. ICCs promote slow waves of intestinal motility. When mice develop constipation, the basement membrane of ICCs dissolves into the colonic wall, disrupting connections with the surrounding tissue. Nuclei atrophy to varying degrees, and the number of ICCs and c-kit-positive cells decreases significantly. The c-kit receptor is crucial for ICC development, so c-kit can be used as an ICC marker for immunohistochemistry.
[0066] 5-HT must bind to its corresponding receptors to exert its effects. 5-HT4R (5-hydroxytryptamine receptor 4) is expressed in both the central and peripheral nervous systems. Peripherally, it is primarily located in enteric neurons, enterochromaffin cells, and smooth muscle cells; centrally, it is primarily distributed in enteric neurons and enterochromaffin cells in the basal ganglia, hippocampus, frontoparietal cortex, and hypothalamus. Activation of 5-HT4 receptors promotes acetylcholine release and gastrointestinal smooth muscle contraction. 5-HT4 receptor agonists, such as prucalopride and cisapride, are commonly used clinically to treat patients with irritable bowel syndrome. Their physiological effects include reducing visceral sensitivity, regulating gastrointestinal motility, and modulating endocrine function.
[0067] Interstitial cells of Caja (ICC) in the gastrointestinal tract can respond to intestinal neurotransmitters to coordinate gastrointestinal motility. They specifically express tyrosine kinase receptor protein (c-kit), and the abundance of ICC cells is positively correlated with constipation symptoms. Immunohistochemistry results showed that compared with group C, the amount of c-kit protein in group M was significantly reduced, and the abundance of ICC cells was reduced; while each treatment group could effectively increase the abundance of ICC cells, and the effect was most obvious in group H ( Figure 3 G).
[0068] There is evidence that 5-HT not only regulates the development of enteric nerves and directly affects intestinal motility, but also affects the central nervous system, thereby indirectly affecting intestinal function. Therefore, a decrease in the release of 5-HT from the central nervous system may lead to brain development defects and constipation. Figure 4 As shown, the production of 5-HT in the brain of mice in group M was significantly lower than that in group C (p < 0.01) (Figure 4A), and the expression of 5-HT receptor 4 (5-HT4R) was significantly decreased ( Figure 4B and C). Compared with the M group, treatment with the positive drug and NCU-04 significantly increased 5-HT production and 5-HT4R expression. In particular, the high dose of NCU-04 had the greatest therapeutic effect. These results suggest that NCU-04 administration may improve constipation by regulating brain 5-HT production and 5-HT4R expression.
[0069] To analyze the effect of Lactobacillus paracasei NCU-04 on the intestinal microbial diversity of constipation mouse models, we used 16S rDNA high-throughput sequencing to analyze the feces of each group of mice. The results of the α-diversity assessment of the intestinal flora showed that ( Figure 5 AC), compared with group C, the α-diversity of intestinal microorganisms in group M, such as Simpson, Shannon, and Pielou_e indices, was significantly reduced (p<0.01), while group H was able to effectively reverse the reduction of α diversity (p<0.01). PCoA principal component analysis was used to further evaluate the β-diversity of the intestinal flora of mice in each group. Compared with group C, the β-diversity of intestinal microorganisms in group M mice changed, and NCU-04 administration effectively reversed this change ( Figure 5 D).
[0070] At the family level of gut microbiota composition (Figure 5E), several bacterial families, including s24-7, Bacteroidetes, Prevotellaceae, and Lactobacillaceae, were relatively enriched in Group C, while Rikenellaceae and Porphyromonadaceae were enriched in Group M. After treatment, the abundance of bacterial families such as s24-7 and Rikenellaceae increased and decreased, respectively (Figure 5F and G). In particular, the decrease in the abundance of Rikenellaceae and Porphyromonadaceae, and the increase in the abundance of Prevotellaceae and Lactobacillaceae, were most prominent in Group H, which also had a microbial profile most similar to that of Group C. At the genus level, compared with Group C, Group M showed increased abundance of Odoribacter, Rikenella, and Parabacteroides, and decreased abundance of Prevotella and Lactobacillus (Figure 5H). Notably, the relative abundance of Odoribacter decreased significantly in group H, while the relative abundance of Prevotella increased compared with group M (Figure 5I-J). The changing trends of other genera in group H, including Rickenella, Prabaceroides, and Lactobacillus, were similar to those of Odoribacter or Prevotella, indicating that the microbial composition between groups H and C was similar (Figure 5H). Interestingly, correlation analysis revealed that 5-HT and MTL were significantly positively correlated with Provetella but negatively correlated with Rickenella and Odoribacter (Figure 5K). In contrast, PYY and VIP were negatively correlated with Prevotella but positively correlated with Rickenella and Odoribacter (Figure 5K). However, no significant correlations were found between Lactobacillus and these four regulated neurotransmitters. These results suggest that the gut microbiota may be involved in regulating the synthesis and secretion of intestinal neurotransmitters or peptides, contributing to intestinal motility and normal defecation. Collectively, these results demonstrate that NCU-04 effectively restored the disturbed gut microbiota in constipated mice, characterized by improved microbial diversity and composition of the gut microbiota.
[0071] Example 4 5-HT acts through the brain-gut axis to alleviate depressive-like behavior caused by constipation 5-HT is a key neurotransmitter in the brain-gut axis, involved in regulating intestinal secretion, intestinal motility, and gastrointestinal sensory function. It is also associated with depression and anxiety. To further explore the role of NCU-04 in improving depression in constipated mice by regulating 5-HT levels, we used a tryptophan hydroxylase inhibitor to inhibit 5-HT synthesis in constipated mice and designed relevant animal experiments ( Figure 6 A).
[0072] Test groups: (1) Blank group: (N=12, divided into two cages) No treatment was performed.
[0073] (2) Model group: (N=12 mice, divided into two cages) Each mouse was gavaged with 200 μl of 1.5 mg / kg loperamide suspension, twice a day, for 5 consecutive days.
[0074] (3) High-dose group: (N=12, divided into two cages) In addition to the model group, 200 μl of 1×10 9 CFU of Lactobacillus paracasei were administered orally for 14 consecutive days.
[0075] (4) High dose + 5-HT inhibitor (chlorophenylalanine PCPA): (N=12, divided into two cages) After the model was successfully established, a high dose of Lactobacillus paracasei was given by gavage and then 100 ul of chlorophenylalanine (300 mg / kg) was injected intraperitoneally, once a day for 3 consecutive days.
[0076] PCPA is a selective, irreversible inhibitor of tryptophan hydroxylase, the rate-limiting enzyme in serotonin (5-HT) synthesis. Animal Experiments 1. Behavioral Experiment: Assessing Depression Caused by Decreased 5-HT (1) Sugar water preference experiment: Sugar water acclimation training was conducted 72 hours before the experiment. Two water bottles were placed in each cage: one containing 1% sugar solution and the other containing tap water. The positions of the two water bottles were rotated every 12 hours. After acclimation to sugar water, mice were deprived of both food and water for 23 hours. Sugar water preference experiments were conducted at 7:00 PM on days 0 and 2. Each cage was given one bottle containing 1% sugar water and one bottle containing tap water, with free access to water. Sugar water and tap water consumption were measured 2 hours later, and the sugar water preference rate was calculated using the formula: sugar water preference rate = sugar water consumption / (sugar water consumption + tap water consumption) × 100%.
[0077] (2) Tail suspension test 60 minutes before the experiment, mice were moved to a quiet testing room to reduce animal stress. During the experiment, the mice's tails were secured with tape and hung from a test rack. The experiment lasted 6 minutes and was recorded using a high-definition digital camera. The total time the mice remained immobile for the next 4 minutes was then recorded in a double-blind manner.
[0078]
Biochemical indicators
[0079] 3. Immunohistochemistry for 5-HT4R (Serotonin Transporter) (1) Dehydration and paraffin embedding: The colorectal tissue and brain tissue of each group of mice were selected, fixed in 4% paraformaldehyde, and dewaxed; (2) Sectioning: Cutting fixed samples into very thin tissue sections, usually 4-6 µm; (3) Antigen retrieval: Place the slide in a dish containing antigen retrieval solution and boil it (10 min). After cooling to room temperature, wash it twice with PBS buffer. (4) Blocking of endogenous catalase: Incubate in 3% H2O2 aqueous solution for 8 min in the dark, and rinse twice with PBS buffer; (5) Serum blocking: add 5% calf serum and incubate at room temperature for 30 min; (6) Antibody labeling: Prepare the primary antibody and select the corresponding secondary antibody according to the antibody instructions. Incubate the primary antibody at 4°C overnight (protected from light) and incubate the secondary antibody at room temperature for 40 min. (7) Antibody staining: Add DAB working solution and incubate in the dark for 8 min. After rinsing with ddH2O to terminate the reaction, add hematoxylin for 30 s and rinse with ddH2O for 8 min. (8) Microscopic analysis: Observe and record the expression of 5-HT4R under a microscope.
[0080] 4. Immunofluorescence detection of BDNF: (brain-derived neurotrophic factor) (1) Brain tissues of mice in each group were selected and dewaxed, serum blocked, and incubated with antibodies; (2) counterstain the cell nuclei with DPAI to quench tissue autofluorescence, and then seal the slides; (3) Finally, the samples were analyzed by fluorescence microscopy.
[0081] Test results and analysis: The above test results are as follows Figure 6 shown.
[0082] The results of the sucrose water preference experiment showed that compared with the C group, the intake of sucrose water by mice in the M and P groups was significantly reduced, while the sucrose consumption was significantly increased after administration of NCU-04 ( p< 0.01)( Figure 6 B).
[0083] In the tail suspension test, the immobility time of mice in each group was different. p< 0.01) and P group ( p< 0.01) was significantly longer than that of group H ( Figure 6 C).
[0084] In addition, the 5-HT content in the colorectal tissues of mice in each group was detected by ELISA. The results showed that compared with the C group, the M ( p< 0.01) and P group ( p< 0.01) decreased significantly, while the 5-HT content in group H increased ( p< 0.01)( Figure 6 D). Detection of 5-HT content in the brain tissue of mice in each group also showed similar results ( Figure 6 E).
[0085] By detecting the 5-HT content in colon tissue and brain tissue using an ELISA kit, it was found that the 5-TH content in the colon and brain decreased after the addition of inhibitors. The brain-enteric neuroendocrine cells connect the brain and intestine through the neuro-endocrine-immune network, and regulate the secretion of neurotransmitters through the nervous system to maintain the normal operation of the "brain-gut axis". 5-hydroxytryptamine (5-HT) is a key neurotransmitter in the brain-gut axis. 90% of the human body's 5-HT is synthesized in the intestine and distributed in enterochromaffin cells, participating in regulating colon secretion, intestinal motility and gastrointestinal sensory function.
[0086] Immunohistochemistry was used to detect 5-HT related receptors in brain tissue. The results showed that compared with the M and P groups, the expression of 5-HT4R in the C and H groups was higher ( Figure 6 F).
[0087] Research on the effects of 5-HT on intestinal motility has spanned over 50 years. 5-HT4 receptor agonists (trade name: cisapride) are clinically used as prokinetic drugs to treat constipation. They are commonly used to treat constipation. Once in the body, 5-HT levels can be increased through its own metabolites or by improving the composition of the intestinal flora, thereby alleviating symptoms of decreased colonic motility. However, some studies have found that 5-HT levels vary significantly between different types of constipation. This may be because 5-HT requires activation of the corresponding 5-HT receptor to exert its effects. Furthermore, 5-HT can be inactivated by transport via the serotonin transporter (SERT), thereby terminating the effect.
[0088] 5-HT4 receptors are expressed in both the central and peripheral nervous systems. In the periphery, they are primarily located in enteric neurons, enterochromaffin cells, and smooth muscle cells; in the central nervous system, they are primarily distributed in the basal ganglia, hippocampus, frontoparietal cortex, hypothalamus, and other areas of the gut. Activation of 5-HT4 receptors can promote acetylcholine release and gastrointestinal smooth muscle contraction. 5-HT4 receptor agonists, such as prucalopride and cisapride, are commonly used clinically to treat patients with irritable bowel syndrome. Their physiological effects include reducing visceral sensitivity, regulating gastrointestinal motility, and modulating endocrine function.
[0089] Other studies have shown that the onset of depression is related to the apoptosis of hippocampal neurons, the reduction of hippocampal volume, and the loss of some neurons. It has been found that many acute or chronic stress stimuli can reduce the expression of BDNF in hippocampal tissue. Studies have shown that the serum level of BDNF in patients with depression is significantly lower than that of normal people, but it can be significantly increased under the treatment of antidepressants. Li et al. found that in the comparison of serum BDNF levels, patients with major depressive disorder (MDD) had significantly lower levels than the normal control group. The situation that the serum BDNF level of patients with depression is lower than that of the normal control group can be improved after treatment with antidepressants. The brain BDNF level of patients with depression is significantly lower than that of normal people, so we used immunofluorescence to further detect the expression of BDNF in each group of mice. The results further revealed that the content of BDNF in the M and P groups was low, while the expression level of BDNF in the H group was increased ( Figure 6 G).
[0090] The above results indicate that Lactobacillus paracasei can improve the symptoms of depression in mice by regulating the expression of 5-HT and increasing the content of BDNF.
[0091] The above description is only a preferred specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any technician familiar with the technical field, within the technical scope disclosed by the present invention, who makes equivalent replacements or changes based on the technical solution and inventive concept of the present invention, should be covered by the scope of protection of the present invention.
Claims
1. A strain of Lactobacillus paracasei NCU-04, characterized in that The Lactobacillus paracasei ( Lactobacillus paracasei )NCU-04 was deposited in the General Microbiology Center of China Microorganism Culture Collection on August 8, 2022, with the deposit number CGMCC No.25506, and the deposit address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
2. Lactobacillus paracasei NCU-04 according to claim 1, is characterized in that, The 16S rDNA of the Lactobacillus paracasei NCU-04 has a nucleotide sequence as shown in SEQ ID NO.
1.
3. Lactobacillus paracasei NCU-04 according to claim 1, is characterized in that, The Lactobacillus paracasei NCU-04 is screened from feces of healthy breast-fed infants.
4. A microbial agent, characterized in that: The microbial agent contains the Lactobacillus paracasei NCU-04 or its fermentation liquid or freeze-dried powder according to claim 1.
5. A product, characterized in that The product contains the Lactobacillus paracasei NCU-04 described in any one of claims 1 to 3 or the microbial agent described in claim 4.
6. Application of Lactobacillus paracasei NCU-04 according to claim 1 in preparing an antibacterial agent.
7. The use according to claim 6, characterized in that: The antibacterial agent can inhibit one or more of Salmonella typhimurium, Shigella flexneri, beta-hemolytic streptococcus, Shigella dysenteriae, Escherichia coli O157, Staphylococcus enteritidis, Listeria monocytogenes and Staphylococcus aureus.
8. Use of the Lactobacillus paracasei NCU-04 according to claim 1 in preparing a medicine for improving constipation.
9. Use of Lactobacillus paracasei NCU-04 according to claim 1 in preparing medicines for treating colitis.
10. Use of the Lactobacillus paracasei NCU-04 according to claim 1 in the preparation of a medicine for improving constipation accompanied by depressive-like behavior symptoms.
Citation Information
Patent Citations
Lactobacillus paracasei and application thereof
CN111560331A
Lactobacillus paracasei Lc19 and microbial preparation containing lactobacillus paracasei Lc19
CN113201467A
Lactobacillus paracasei capable of antagonizing pharyngitis pathogenic bacterium beta hemolytic streptococcus
CN113249244A
Lactobacillus paracasei CCFM1229 for relieving depressive mood and application thereof
CN114717148A
Lactobacillus paracasei for preventing infant streptococcus infection and application of lactobacillus paracasei
CN114717157A
Cited By
Lactobacillus paracasei metaplasm with constipation relieving effect and application of lactobacillus paracasei metaplasm
CN119639612A
Lactobacillus paracasei metaplasm with constipation relieving effect and application of lactobacillus paracasei metaplasm
CN119685204A
Lactobacillus paracasei and application thereof
CN120005776A
A Lactobacillus paracasei and its application
CN120005776B
Lactobacillus paracasei MDL525 and application thereof in preparation of product for preventing and treating anxiety disorder and / or depression
CN121136883A
